CHASE Registry of Patients With Pulmonary Hypertension Receiving Targeted Therapy

Who May Qualify: - Sign willing to sign a consent form; - Between the ages of 18 and 85; - Clinical diagnosis of pulmonary hypertension, using or planning to use pulmonary hypertension targeted drugs (including any one or more of the following: prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase agonists and prostacyclin receptor agonists). Who Should NOT Join This Trial: - Have a history of mental illness or drug or poison addiction, and can not sign willing to sign a consent form or can not cooperate with the experimental study; - Patients with malignant tumor and other diseases and life expectancy of less than half a year; - Short-term (less than 2 weeks) patients taking targeted drugs for pulmonary hypertension Always talk to your doctor about whether this trial is right for you.